Advertisement
Advertisement


U.S. News

Merck to Partner on HIV Projects

July 12, 2011

Merck & Co. is joining HIV research projects led by two major U.S. universities, a top official with the pharmaceutical firm has announced. "Collaboration has been the hallmark of much of the progress made against HIV since the virus was first identified 30 years ago," said Daria Hazuda, Merck's research laboratories vice president.

Merck will become the only pharmaceutical partner in a new project steered by the University of North Carolina-Chapel Hill. A team including 19 investigators from UNC and eight other universities will look for ways to purge persistent HIV infection from the body.

Concurrently, Merck will work with researchers at the University of California-San Francisco on a five-year effort to define and better understand HIV's reservoirs and test potential treatments.

The National Institute of Allergy and Infectious Diseases is the primary funder for both research initiatives. Merck will not receive any funding for its participation.

Back to other news for July 2011

Adapted from:
Wall Street Journal
07.11.2011; Drew Fitzgerald




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
No Proof of New HIV Cure, Despite Headlines -- Here's What We Know
The Only Cases of HIV Cure or Remission
Beyond the Berlin Patient: How Researchers Are Now Trying to Cure More HIV-Positive People (Video)
What Would an HIV Cure Mean for You?

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.